NCT07123727Phase 2Recruiting

A Study to Examine Anktiva for the Treatment of COVID-19.

Study sponsor: ImmunityBio, Inc. · IBRX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-03Estimated
Enrollment · participants40Estimated
Source updated2026-09-24Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Primary completion date changed

Before: Jul 2026. After: Mar 2027.

Check registry source